Mind-NRG
Geneva
About Mind-NRG
Mind-NRG, based out of Switzerland, is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood - brain barrier through a receptor-mediated transport to reach its target in the brain. NRG-101 will be developed to treat disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia. Mind-NRG will initially focus on conducting in vitro and in vivo experiments to further explore the mechanism of action of the peptide and to assess the activity of NRG-101 in a variety of relevant disease models.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $23.7M
- Funding stage: Early Stage Venture
- Last round: Series B (Sep 2013)
- Website: mind-nrg.com
- Phone: +41 22 737 00 00
Industries & Categories
Biotechnology, Medical Device, Neuroscience
Canonical: https://fsome.com/organization/mind-nrg-3535401 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.